Waverley Pharma Inc.
WAVE.V
TSX
| 03/31/2026 | 09/30/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 1,959.58% | 729.98% | 729.98% | 181.06% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 1,959.58% | 729.98% | 729.98% | 181.06% |
| Cost of Revenue | -- | 740.70% | 304.88% | 304.88% | 125.75% |
| Gross Profit | -- | 1,784.13% | 2,301.14% | 2,301.14% | 331.28% |
| SG&A Expenses | -- | 18.56% | -24.40% | -24.40% | -37.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 37.30% | 9.75% | 9.75% | -0.37% |
| Operating Income | -- | 75.62% | 73.38% | 73.38% | 45.51% |
| Income Before Tax | -- | 83.82% | 82.41% | 82.41% | 66.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | 83.75% | 82.41% | 82.41% | 66.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | 83.75% | 82.41% | 82.41% | 66.99% |
| EBIT | -- | 75.62% | 73.38% | 73.38% | 45.51% |
| EBITDA | -- | 77.16% | 70.07% | 70.07% | 38.32% |
| EPS Basic | -- | 83.44% | 82.14% | 82.14% | 66.67% |
| Normalized Basic EPS | -- | 72.22% | 70.54% | 70.54% | 42.31% |
| EPS Diluted | -- | 86.26% | 75.14% | 75.14% | 50.92% |
| Normalized Diluted EPS | -- | 72.22% | 70.54% | 70.54% | 42.31% |
| Average Basic Shares Outstanding | -- | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | -- | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |